Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas?
| Autor: | Carla Carrilho, Jorge S. Reis-Filho, Fernando Schmitt, Dina Leitão, Silvana G.A. Ribeiro, Carlos A. Ribeiro, Carla Valenti |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
Pathology medicine.medical_specialty Thyroid Nuclear Factor 1 Lung Neoplasms Adenocarcinoma Endometrium Sensitivity and Specificity Pathology and Forensic Medicine Diagnosis Differential Immunoenzyme Techniques Prostate Biomarkers Tumor medicine Humans Neoplasm Metastasis Lung cancer Cell Nucleus Homeodomain Proteins Lung business.industry Nuclear Proteins Cell Biology medicine.disease digestive system diseases medicine.anatomical_structure Immunohistochemistry Female Differential diagnosis business Transcription Factors |
| Zdroj: | Pathology - Research and Practice. 196:835-840 |
| ISSN: | 0344-0338 |
| Popis: | To evaluate the immunohistochemical expression of thyroid transcription factor 1 (TTF1) in primary and metastatic pulmonary adenocarcinomas, and test the diagnostic accuracy of this antibody, two surgical pathologists independently evaluated 34 cases of adenocarcinomas in the lung without clinical data and tried to distinguish between primary and metastatic cases using histological criteria exclusively. Thirteen cases were primary in the lung and 21 were metastases of extrapulmonary adenocarcinomas: 6 from the endometrium, 4 from the ovary, 3 from the colon, 2 from the kidney, 2 from the breast, 2 from the liver and 1 from the prostate. Afterward, the immunoreactivity of TTF1 in these neoplasms was evaluated and correlated with morphological and clinical data. The two pathologists were able to diagnose only 5 out of 13 cases of primary lung adenocarcinomas (sensitivity of 38.46%) and also misdiagnosed two primary malignancies as metastases. After correlation with TTF1 data, the sensitivity increased to 61.53%. The specificity of TTF1 was 100%. In conclusion, TTF1 is a highly specific marker for primary lung adenocarcinomas, and should be included in a panel of antibodies for the differential diagnosis between primary and metastatic adenocarcinomas of the lung. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect